Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
2.
Andrologia ; 45(2): 128-34, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22731390

RESUMO

Previous studies have shown that alpha1-adrenergic receptor antagonists may alter seminal vesicle contractility and impair fertility in male rats. This study was designed to investigate the effects of terazosin on the catalase expression in the seminal vesicles and the lipid peroxidation of the seminal fluid in normal adult rats. Wistar rats were treated with terazosin (1.2 mg kg(-1) body weight, given orally every second day) for 120 days. Catalase expression was assessed immunohistochemically in tissue sections of the seminal vesicles, and lipid peroxidation was estimated by measuring the malondialdehyde (MDA) levels in the seminal vesicles' fluid. The seminal vesicles in terazosin-treated rats were particularly distended in comparison with those of controls, and their secreting epithelium was suppressed. Cytoplasmic catalase expression in the secreting epithelial cells (% of cells) was increased in terazosin-treated specimens in comparison with controls (76.1 ± 17.1 versus 51.3 ± 25.1, P = 0.005). MDA levels (µm) were also higher in samples from treated subjects in comparison with controls (2.67 ± 1.19 versus 1.39 ± 0.19, P = 0.01). Although the direct effect of terazosin treatment on the seminal vesicles is that of impaired contractility, an indirect effect is that on fertility by increasing lipid peroxidation in the seminal fluid and/or through degrading of hydrogen peroxide that is essential for sperm capacitation.


Assuntos
Antagonistas de Receptores Adrenérgicos alfa 1/toxicidade , Catalase/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Prazosina/análogos & derivados , Glândulas Seminais/efeitos dos fármacos , Glândulas Seminais/metabolismo , Animais , Fertilidade/efeitos dos fármacos , Masculino , Prazosina/toxicidade , Ratos , Ratos Wistar , Glândulas Seminais/patologia
3.
Urologe A ; 43(2): 168-71, 2004 Feb.
Artigo em Alemão | MEDLINE | ID: mdl-14991118

RESUMO

TARGET: The approximate incidence of indinavir urolithiasis in HIV positive patients receiving the drug is 10%. The exact mechanism of lithogenesis is still unknown. Pure indinavir stones are radiolucent on plane abdominal X-ray or CT scan. Indinavir urolithiasis can be associated with acute unilateral renal colic or severe azotaemia. MATERIAL AND METHODS: 20 HIV patients were treated conservatively by increasing oral fluid intake (urine production of 2 l/day and more), discontinuation of indinavir therapy for 1 week and acidification of urine with l-methionin (urine pH 5,3-5,8). Some patients were additionally treated with endoscopic procedures. RESULTS: In all patients renal function normalized. Increase of oral fluid intake, especially during the first 2 hours after intake of indinavir and during night prevented recurrence of indinavir urolithiasis. CONCLUSION: HIV positive patients with renal colic or renal insufficiency and roentgenological absence of radio-opaque stone formations should make the urologist consider indinavir urolithiasis as a possible diagnosis.


Assuntos
Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Hidratação/métodos , Indinavir/administração & dosagem , Indinavir/efeitos adversos , Metionina/uso terapêutico , Cálculos Urinários/tratamento farmacológico , Cálculos Urinários/etiologia , Síndrome da Imunodeficiência Adquirida/complicações , Adulto , Feminino , Inibidores da Protease de HIV/administração & dosagem , Inibidores da Protease de HIV/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Cálculos Urinários/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA